Neuro-inflammatory mechanisms in developmental disorders associated with intellectual disability and autism spectrum disorder: A neuro-immune perspective

CNS and Neurological Disorders - Drug Targets

Volumn 15, Issue 4, 2016, Pages 448-463

  Di Marco, Barbara ^a   Bonaccorso, Carmela M ^b   Aloisi, Elisabetta ^c,d   D’Antoni, Simona ^a   Catania, Maria V ^a,b  

^a INSTITUTE OF NEUROLOGICAL SCIENCES   (Italy)

^b OASI RESEARCH INSTITUTE IRCCS   (Italy)

^c INSTITUT FRANÇOIS MAGENDIE   (France)

^d UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Astrocytes; Autism; Cytokines; Gliosis; Immune cells; Mental retardation; Microglia; Neurodevelopment

Indexed keywords

BRAIN PROTEIN; COPPER ZINC SUPEROXIDE DISMUTASE; EOTAXIN; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GELATINASE B; GLIAL FIBRILLARY ACIDIC PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 12; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 6; INTERLEUKIN 8; METHYL CPG BINDING PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE;

ARTICLE; AUTISM; DEVELOPMENTAL DISORDER; FRAGILE X SYNDROME; GENE MUTATION; HUMAN; IMMUNE RESPONSE; INTELLECTUAL IMPAIRMENT; LONG TERM POTENTIATION; MICROGLIA; MOLECULAR BIOLOGY; NERVE CELL PLASTICITY; NERVE EXCITABILITY; NERVOUS SYSTEM DEVELOPMENT; NERVOUS SYSTEM INFLAMMATION; NEUROCHEMISTRY; NEUROIMAGING; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; POSITRON EMISSION TOMOGRAPHY; PRENATAL EXPOSURE; RETT SYNDROME; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; COMPLICATION; IMMUNOPATHOLOGY; METABOLISM; PATHOLOGY;

AUTISM SPECTRUM DISORDER; CYTOKINES; HUMANS; IMMUNE SYSTEM DISEASES; INTELLECTUAL DISABILITY; MICROGLIA;

EID: 84964054440     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527315666160321105039     Document Type: Article

References (228)

1. American Psychiatric Association. A Diagnostic and Statistical Manual of Mental Disorders (DSM-5). American Psychiatric Publishing, 2013.
2. Developmental Disabilities Monitoring Network Surveillance, Principal Investigators. Centers for Disease Control and Prevention CDC. Prevalence of autism spectrum disorder among children aged 8 years - autism and developmental disabilities monitoring network, 11 sites, United States, 2010. MMWR Surveill Summ 2014; 63(2): 1-21.
3. Voineagu I, Eapen V. Converging Pathways in Autism Spectrum Disorders: Interplay between Synaptic Dysfunction and Immune Responses. Front Hum Neurosci 2013; 7(7): 738.
4. Onore C, Careaga M, Ashwood P. The role of immune dysfunction in the pathophysiology of autism. Brain Behav Immun 2012; 26(3): 383-92.
5. McDougle CJ, Landino SM, Vahabzadeh A, et al. Toward an immune-mediated subtype of autism spectrum disorder. Brain Res 2014; S0006-8993(14): 01297-9.
6. Goyal DK, Miyan JA. Neuro-immune abnormalities in autism and their relationship with the environment: a variable insult model for autism. Front Endocrinol 2014; 7(5): 29.
7. Amor S, Puentes F, Baker D, van der Valk P. Inflammation in neurodegenerative diseases. Immunology 2010; 129(2): 154-69.
8. Alvarez-Arellano L, de León-Guerrero SD, Meza-Sosa KF, Jiménez-Ferrer I, Pérez-Martínez L. Neurodegenerative disorders and inflammation. In: Pérez-Martínez L, Pedraza-Alva G, Ferat Osorio E. Eds: Molecular Aspects of Inflammation. Kerala, Research Signpost, 2013; pp. 173-207.
9. Deverman BE, Patterson PH. Cytokines and CNS development. Neuron 2009; 64(1): 61-78.
10. Vezzani A, Viviani B. Neuromodulatory properties of inflammatory cytokines and their impact on neuronal excitability. Neuropharmacology 2014; S0028-3908(14): 00402-X.
11. Donzis EJ, Tronson NC. Modulation of learning and memory by cytokines: signaling mechanisms and long term consequences. Neurobiol Learn Mem 2014; 115: 68-77.
12. Ransohoff RM, Brown MA. Innate immunity in the central nervous system. J Clin Invest 2012; 122(4): 1164-71.
13. Di Filippo M, Sarchielli P, Picconi B, Calabresi P. Neuroinflammation and synaptic plasticity: theoretical basis for a novel, immune-centred, therapeutic approach to neurological disorders. Trends Pharmacol Sci 2008; 29(8): 402-12.
14. Di Filippo M, Chiasserini D, Gardoni F, et al. Effects of central and peripheral inflammation on hippocampal synaptic plasticity. Neurobiol Dis 2013; 52: 229-36.
15. Marin I, Kipnis J. Learning and memory and the immune system. Learn Mem 2013; 20(10): 601-6.
16. Bilbo SD, Schwarz JM. Early-life programming of later-life brain and behavior: a critical role for the immune system. Front Behav Neurosci 2009; 3: 14.
17. Meyer U, Feldon J, Dammann O. Schizophrenia and autism: both shared and disorder-specific pathogenesis via perinatal inflammation? Pediatr Res 2011; 69(5-2): 26-33.
18. Bale TL, Baram TZ, Brown AS, et al. Early life programming and neurodevelopmental disorders. Biol Psychiatry 2010; 68(4): 314-9.
19. Stolp HB, Dziegielewska KM. Role of developmental inflammation and blood-brain barrier dysfunction in neurodevelopmental and neurodegenerative diseases. Neuropathol Appl Neurobiol 2009; 35(2): 132-46.
20. Dalton P, Deacon R, Blamire A, et al. Maternal neuronal antibodies associated with autism and a language disorder. Ann Neurol 2003; 53(4): 533-7.
21. Braunschweig D, Ashwood P, Krakowiak P, et al. Autism: maternally derived antibodies specific for fetal brain proteins. Neurotoxicology 2008; 29(2): 226-31.
22. Croen LA, Braunschweig D, Haapanen L, et al. Maternal midpregnancy autoantibodies to fetal brain protein: the early markers for autism study. Biol Psychiatry 2008; 64(7): 583-8.
23. Patterson PH. Maternal infection and immune involvement in autism. Trends Mol Med 2011; 17(7): 389-94.
24. Kreutzberg GW. Microglia: a sensor for pathological events in the CNS. Trends Neurosci 1996; 19(8): 312-8.
25. Hanisch UK, Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat Neurosci 2007; 10(11): 1387-94.
26. Rezaie P, Male D. Colonisation of the developing human brain and spinal cord by microglia: a review. Microsc Res Tech 1999; 45(6): 359-82.
27. Ginhoux F, Greter M, Leboeuf M, et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 2010; 330(6005): 841-5.
28. Salter MW, Beggs S. Sublime microglia: expanding roles for the guardians of the CNS. Cell 2014; 158(1): 15-24.
29. Ransohoff RM, Perry VH. Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol 2009; 27: 119-45.
30. Kettenmann H, Kirchhoff F, Verkhratsky A. Microglia: new roles for the synaptic stripper. Neuron 2013; 77(1): 10-8.
31. Davalos D, Grutzendler J, Yang G, et al. ATP mediates rapid microglial response to local brain injury in vivo. Nat Neurosci 2005; 8(6): 752-8.
32. Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005; 308(5726): 1314-8.
33. Blinzinger K, Kreutzberg G. Displacement of synaptic terminals from regenerating motoneurons by microglial cells. Z Zellforsch Mikrosk Anat 1968; 85(2): 145-57.
34. Graeber MB, Bise K, Mehraein P. Synaptic stripping in the human facial nucleus. Acta Neuropathol 1993; 86(2): 179-81.
35. Tremblay MÈ, Stevens B, Sierra A, Wake H, Bessis A, Nimmerjahn A. The role of microglia in the healthy brain. J Neurosci 2011; 31(45): 16064-9.
36. Paolicelli RC, Bolasco G, Pagani F, et al. Synaptic pruning by microglia is necessary for normal brain development. Science 2011; 333(6048): 1456-8.
37. Schafer DP, Lehrman EK, Kautzman AG, et al. Microglia sculpt postnatal neural circuits in an activity and complement-dependent manner. Neuron 2012; 74(4): 691-705.
38. Wake H, Moorhouse AJ, Jinno S, Kohsaka S, Nabekura J. Resting microglia directly monitor the functional state of synapses in vivo and determine the fate of ischemic terminals. J Neurosci 2009; 29(13): 3974-80.
39. Pascual O, Ben Achour S, Rostaing P, Triller A, Bessis A. Microglia activation triggers astrocyte-mediated modulation of excitatory neurotransmission. Proc Natl Acad Sci USA 2012; 109(4): 197-205.
40. Alliot F, Godin I, Pessac B. Microglia derive from progenitors, originating from the yolk sac, and which proliferate in the brain. Brain Res Dev Brain Res 1999; 117(2): 145-52.
41. Zusso M, Methot L, Lo R, Greenhalgh AD, David S, Stifani S. Regulation of postnatal forebrain amoeboid microglial cell proliferation and development by the transcription factor Runx1. J Neurosci 2012; 32(33): 11285-98.
42. Nikodemova M, Kimyon RS, De I, Small AL, Collier LS, Watters JJ. Microglial numbers attain adult levels after undergoing a rapid decrease in cell number in the third postnatal week. J Neuroimmunol 2015; 278: 280-8.
43. Bilbo SD, Schwarz JM. The immune system and developmental programming of brain and behavior. Front Neuroendocrinol 2012; 33(3): 267-86.
44. Crain JM, Nikodemova M, Watters JJ. Microglia express distinct M1 and M2 phenotypic markers in the postnatal and adult central nervous system in male and female mice. J Neurosci Res 2013; 91(9): 1143-51.
45. Harry GJ, Kraft AD. Microglia in the developing brain: a potential target with lifetime effects. Neurotoxicology 2012; 33(2): 191-206.
46. Bilbo SD, Biedenkapp JC, Der-Avakian A, Watkins LR, Rudy JW, Maier SF. Neonatal infection-induced memory impairment after lipopolysaccharide in adulthood is prevented via caspase-1 inhibition. J Neurosci 2005; 25(35): 8000-9.
47. Saijo K, Glass CK. Microglial cell origin and phenotypes in health and disease. Nat Rev Immunol 2011; 11(11): 775-87.
48. Yirmiya R, Goshen I. Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav Immun 2011; 25(2): 181-213.
49. Rothwell NJ, Luheshi GN. Interleukin 1 in the brain: biology, pathology and therapeutic target. Trends Neurosci 2000; 23(12): 618-25.
50. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87(6): 2095-147.
51. Gosselin D, Rivest S. Role of IL-1 and TNF in the brain: twenty years of progress on a Dr. Jekyll/Mr. Hyde duality of the innate immune system. Brain Behav Immu 2007; 21(3): 281-9.
52. Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol 2009; 27: 229-65.
53. Saha RN, Liu X, Pahan K. Up-regulation of BDNF in astrocytes by TNF-alpha: a case for the neuroprotective role of cytokine. J Neuroimmune Pharmacol 2006; 1(3): 212-22.
54. Stawarski M, Stefaniuk M, Wlodarczyk J. Matrix metalloproteinase-9 involvement in the structural plasticity of dendritic spines. Front Neuroanat 2014; 8: 68.
55. Giulian D, Young DG, Woodward J, Brown DC, Lachman LB. Interleukin-1 is an astroglial growth factor in the developing brain. J Neurosci 1988; 8(2): 709-14.
56. Dziegielewska KM, Møller JE, Potter AM, Ek J, Lane MA, Saunders NR. Acute-phase cytokines IL-1beta and TNF-alpha in brain development. Cell Tissue Res 2000; 299(3): 335-45.
57. Crampton SJ, Collins LM, Toulouse A, Nolan YM, O’Keeffe GW. Exposure of foetal neural progenitor cells to IL-1β impairs their proliferation and alters their differentiation - a role for maternal inflammation? J Neurochem 2012; 120(6): 964-73.
58. Green HF, Nolan YM. Unlocking mechanisms in interleukin-1β- induced changes in hippocampal neurogenesis--a role for GSK-3β and TLX. Transl Psychiatry 2012; 2: e194.
59. Ma L, Li XW, Zhang SJ, et al. Interleukin-1 beta guides the migration of cortical neurons. J Neuroinflammation 2014; 11: 114.
60. Parnet P, Kelley KW, Bluthé RM, Dantzer R. Expression and regulation of interleukin-1 receptors in the brain. Role in cytokinesinduced sickness behavior. J Neuroimmunol 2002; 125(1-2): 5-14.
61. Vezzani A, Maroso M, Balosso S, Sanchez MA, Bartfai T. IL-1 receptor/Toll-like receptor signaling in infection, inflammation, stress and neurodegeneration couples hyperexcitability and seizures. Brain Behav Immun 2011; 25(7): 1281-9.
62. Gardoni F, Boraso M, Zianni E, et al. Distribution of interleukin-1 receptor complex at the synaptic membrane driven by interleukin-1β and NMDA stimulation. J Neuroinflammation 2011; 8(1): 14.
63. Goshen I, Kreisel T, Ounallah-Saad H, et al. A dual role for interleukin-1 in hippocampal-dependent memory processes. Psychoneuroendocrinology 2007; 32(8-10): 1106-15.
64. Labrousse VF, Costes L, Aubert A, et al. Impaired interleukin-1beta and c-Fos expression in the hippocampus is associated with a spatial memory deficit in P2X(7) receptor-deficient mice. PLoS One 2009; 4(6).
65. Schneider H, Pitossi F, Balschun D, Wagner A, del Rey A, Besedovsky HO. Aneuromodulatory role of interleukin-1beta in the hippocampus. Proc Natl Acad Sci USA 1998; 95(13): 7778-83.
66. Vezzani A, Moneta D, Richichi C, et al. Functional role of inflammatory cytokines and anti-inflammatory molecules in seizures and epileptogenesis. Epilepsia 2002; 43(5): 30-5.
67. Lue LF, Rydel R, Brigham EF, et al. Inflammatory repertoire of Alzheimer’s disease and nondemented elderly microglia in vitro. Glia 2001; 35(1): 72-9.
68. Santello M, Volterra A. TNFα in synaptic function: switching gears. Trends Neurosci 2012; 35(10): 638-47.
69. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 2003; 10(1): 45-65.
70. Han YP, Tuan TL, Wu H, Hughes M, Garner WL. TNF-alpha stimulates activation of pro-MMP2 in human skin through NF- (kappa)B mediated induction of MT1-MMP. J Cell Sci 2001; 114(1): 131-139.
71. Han YP, Nien Y-D, and Warren L. Tumor Necrosis Factor-α- induced Proteolytic Activation of Promatrix Metalloproteinase-9 by Human Skin Is Controlled by Downregulating Tissue Inhibitor of Metalloproteinase-1 and Mediated by Tissue-associated Chymotrypsin-like Proteinase. J Biol Chem 2002; 277(30): 27319-27.
72. Muñoz-Fernández MA, Fresno M. The role of tumour necrosis factor, interleukin 6, interferon-gamma and inducible nitric oxide synthase in the development and pathology of the nervous system. Prog Neurobiol 1998; 56(3): 307-40.
73. Krueger JM. The role of cytokines in sleep regulation. Curr Pharm Des 2008; 14(32): 3408-16.
74. Langhans W, Hrupka B. Interleukins and tumor necrosis factor as inhibitors of food intake. Neuropeptides 1999; 33(5): 415-24.
75. Stellwagen D, Malenka RC. Synaptic scaling mediated by glial TNF-alpha. Nature 2006; 440(7087): 1054-9.
76. Santello M, Bezzi P, Volterra A. TNFα controls glutamatergic gliotransmission in the hippocampal dentate gyrus. Neuron 2011; 69(5): 988-1001.
77. Bauer S, Kerr BJ, Patterson PH. The neuropoietic cytokine family in development, plasticity, disease and injury. Nat Rev Neurosci 2007; 8(3): 221-32.
78. Erta M, Quintana A, Hidalgo J. Interleukin-6, a major cytokine in the central nervous system. Int J Biol Sci 2012; 8(9): 1254-66.
79. Jankowsky JL, Derrick BE, Patterson PH. Cytokine responses to LTP induction in the rat hippocampus: a comparison of in vitro and in vivo techniques. Learning & memory 2000; 7: 400-12.
80. Hama T, Kushima Y, Miyamoto M, Kubota M, Takei N, Hatanaka H. Interleukin-6 improves the survival of mesencephalic catecholaminergic and septal cholinergic neurons from postnatal, two-week-old rats in cultures. Neuroscience 1991; 40(2): 445-52.
81. Pratt L, Ni L, Ponzio NM, Jonakait GM. Maternal inflammation promotes fetal microglial activation and increased cholinergic expression in the fetal basal forebrain: role of interleukin-6. Pediatr Res 2013; 74(4): 393-401.
82. Vallières L, Campbell IL, Gage FH, Sawchenko PE. Reduced hippocampal neurogenesis in adult transgenic mice with chronic astrocytic production of interleukin-6. J Neurosci 2002; 22(2): 486-92.
83. Nakanishi M, Niidome T, Matsuda S, Akaike A, Kihara T, Sugimoto H. Microglia-derived interleukin-6 and leukaemia inhibitory factor promote astrocytic differentiation of neural stem/progenitor cells. Eur J Neurosci 2007; 25(3): 649-58.
84. Bellinger FP, Madamba SG, Campbell IL, Siggins GR. Reduced long-term potentiation in the dentate gyrus of transgenic mice with cerebral overexpression of interleukin-6. Neurosci Lett 1995; 198(2): 95-8.
85. Wei H, Chadman KK, McCloskey DP, et al. Brain IL-6 elevation causes neuronal circuitry imbalances and mediates autism-like behaviors. Biochim Biophys Acta 2012; 1822(6): 831-42.
86. Meyer U, Feldon J, Schedlowski M, Yee BK. Towards an immunoprecipitated neurodevelopmental animal model of schizophrenia. Neurosci Biobehav Rev 2005; 29(6): 913-47.
87. Patterson PH. Immune involvement in schizophrenia and autism: Etiology, pathology and animal models. Behav Brain Res 2009; 204: 313-21.
88. Meyer U, Feldon J, Yee BK. A review of the fetal brain cytokine imbalance hypothesis of schizophrenia. Schizophr Bull 2009; 35(5): 959-72.
89. Meyer U, Feldon J. Epidemiology-driven neurodevelopmental animal models of schizophrenia. Prog Neurobiol 2010; 90(3): 285-326.
90. Shi L, Smith SE, Malkova N, Tse D, Su Y, Patterson PH. Activation of the maternal immune system alters cerebellar development in the offspring. Brain Behav Immun 2009; 23(1): 116-23.
91. Ponzio NM, Servatius R, Beck K, Marzouk A, Kreider T. Cytokine levels during pregnancy influence immunological profiles and neurobehavioral patterns of the offspring. Ann NY Acad Sci 2007; 1107: 118-28.
92. Smith SE, Li J, Garbett K, Mirnics K, Patterson PH. Maternal immune activation alters fetal brain development through interleukin-6. J Neurosci 2007; 27(40): 10695-702.
93. Lubs HA, Stevenson RE, Schwartz CE. Fragile X and X-linked intellectual disability: four decades of discovery. Am J Hum Genet 2012; 90(4): 579-90.
94. Huguet G, Ey E, Bourgeron T. The genetic landscapes of autism spectrum disorders. Annu Rev Genomics Hum Genet 2013; 14: 191-213.
95. Hallmayer J, Cleveland S, Torres A, et al. Genetic heritability and shared environmental factors among twin pairs with autism. Arch Gen Psychiatry 2011; 68(11): 1095-102.
96. Kim YS, Leventhal BL. Genetic epidemiology and insights into interactive genetic and environmental effects in autism spectrum disorders. Biol Psychiatry 2015; 77(1): 66-74.
97. Torres AR, Maciulis A, Stubbs EG, Cutler A, Odell D. The transmission disequilibrium test suggests that HLA-DR4 and DR13 are linked to autism spectrum disorder. Hum Immunol 2002; 63(4): 311-6.
98. Lee LC, Zachary AA, Leffell MS, et al. HLA-DR4 in families with autism. Pediatr Neurol 2006; 35(5): 303-7.
99. Campbell DB, Sutcliffe JS, Ebert PJ, et al. A genetic variant that disrupts MET transcription is associated with autism. Proc Natl Acad Sci USA 2006; 103(45): 16834-9.
100. Torres AR, Sweeten TL, Cutler A, et al. The association and linkage of the HLA-A2 class I allele with autism. Hum Immunol 2006; 67(4-5): 346-51.
101. Heuer L, Braunschweig D, Ashwood P, Van de Water J, Campbell DB. Association of a MET genetic variant with autism-associated maternal autoantibodies to fetal brain proteins and cytokine expression. Transl Psychiatry 2011; 1: e48.
102. Srivastava AK, Schwartz CE. Intellectual disability and autism spectrum disorders: causal genes and molecular mechanisms. Neurosci Biobehav Rev 2014; 46(2): 161-74.
103. Bourgeron T. A synaptic trek to autism. Curr Opin Neurobiol 2009; 19(2): 231-4.
104. Ebert DH, Greenberg ME. Activity-dependent neuronal signalling and autism spectrum disorder. Nature 2013; 493(7432): 327-37.
105. Delorme R, Ey E, Toro R, Leboyer M, Gillberg C, Bourgeron T. Progress toward treatments for synaptic defects in autism. Nat Med 2013; 19(6): 685-94.
106. O’Roak BJ, Vives L, Fu W, et al. Multiplex targeted sequencing identifies recurrently mutated genes in autism spectrum disorders. Science 2012; 338(6114): 1619-22.
107. Bernier R, Golzio C, Xiong B, et al. Disruptive CHD8 mutations define a subtype of autism early in development. Cell 2014; 158(2): 263-76.
108. De Rubeis S, He X, Goldberg AP, et al. Synaptic, transcriptional and chromatin genes disrupted in autism. Nature 2014; 515(7526): 209-15.
109. Iossifov I, O’Roak BJ, Sanders SJ, et al. The contribution of de novo coding mutations to autism spectrum disorder. Nature 2014; 515(7526): 216-21.
110. McDougle CJ, Carlezon WA Jr. Neuroinflammation and autism: toward mechanisms and treatments. Neuropsychopharmacology 2013; 38(1): 241-2.
111. Comi AM, Zimmerman AW, Frye VH, Law PA, Peeden JN. Familial clustering of autoimmune disorders and evaluation of medical risk factors in autism. J Child Neurol 1999; 14(6): 388-94.
112. Croen LA, Grether JK, Yoshida CK, Odouli R, Van de Water J. Maternal autoimmune diseases, asthma and allergies, and childhood autism spectrum disorders: a case-control study. Arch Pediatr Adolesc Med 2005; 159(2): 151-7.
113. Atladóttir HO, Pedersen MG, Thorsen P, et al. Association of family history of autoimmune diseases and autism spectrum disorders. Pediatrics 2009; 124(2): 687-94.
114. Keil A, Daniels JL, Forssen U, et al. Parental autoimmune diseases associated with autism spectrum disorders in offspring. Epidemiology 2010; 21(6): 805-8.
115. Zimmerman AW, Connors SL, Matteson KJ, et al. Maternal antibrain antibodies in autism. Brain Behav Immun 2007; 21(3): 351-7.
116. Singer HS, Morris CM, Gause CD, Gillin PK, Crawford S, Zimmerman AW. Antibodies against fetal brain in sera of mothers with autistic children. J Neuroimmunol 2008; 194(1-2): 165-72.
117. Braunschweig D, Krakowiak P, Duncanson P, et al. Autismspecific maternal autoantibodies recognize critical proteins in developing brain. Transl Psychiatry 2013; 9(3): e277.
118. Garty BZ, Ludomirsky A, Danon YL, Peter JB, Douglas SD. Placental transfer of immunoglobulin G subclasses. Clin Diagn Lab Immunol 1994; 1(6): 667-9.
119. Bake S, Friedman JA, Sohrabji F. Reproductive age-related changes in the blood brain barrier: expression of IgG and tight junction proteins. Microvasc Res 2009; 78(3): 413-24.
120. Nordahl CW, Braunschweig D, Iosif AM, et al. Maternal autoantibodies are associated with abnormal brain enlargement in a subgroup of children with autism spectrum disorder. Brain Behav Immun 2013; 30: 61-5.
121. Martin LA, Ashwood P, Braunschweig D, Cabanlit M, Van de Water J, Amaral DG. Stereotypies and hyperactivity in rhesus monkeys exposed to IgG from mothers of children with autism. Brain Behav Immun 2008; 22(6): 806-16.
122. Singer HS, Morris C, Gause C, Pollard M, Zimmerman AW, Pletnikov M. Prenatal exposure to antibodies from mothers of children with autism produces neurobehavioral alterations: A pregnant dam mouse model. J Neuroimmunol 2009; 211(1-2): 39-48.
123. Bauman MD, Iosif AM, Ashwood P, et al. Maternal antibodies from mothers of children with autism alter brain growth and social behavior development in the rhesus monkey. Transl Psychiatry 2013; 3: e278.
124. Martínez-Cerdeño V, Camacho J, Fox E, et al. Prenatal Exposure to Autism-Specific Maternal Autoantibodies Alters Proliferation of Cortical Neural Precursor Cells, Enlarges Brain, and Increases Neuronal Size in Adult Animals. Cereb Cortex 2016; 26(1): 374-83.
125. Camacho J, Jones K, Miller E, et al. Embryonic intraventricular exposure to autism-specific maternal autoantibodies produces alterations in autistic-like stereotypical behaviors in offspring mice. Behav Brain Res 2014; 266: 46-51.
126. Jyonouchi H, Sun S, Le H. Proinflammatory and regulatory cytokine production associated with innate and adaptive immune responses in children with autism spectrum disorders and developmental regression. J Neuroimmunol 2001; 120(1-2): 170-9.
127. Jyonouchi H, Sun S, Itokazu N. Innate immunity associated with inflammatory responses and cytokine production against common dietary proteins in patients with autism spectrum disorder. Neuropsychobiology 2002; 46(2): 76-84.
128. Ashwood P, Wakefield AJ. Immune activation of peripheral blood and mucosal CD3+ lymphocyte cytokine profiles in children with autism and gastrointestinal symptoms. J Neuroimmunol 2006; 173(1-2): 126-34.
129. Singh VK. Plasma increase of interleukin-12 and interferongamma. Pathological significance in autism. J Neuroimmunol 1996; 66(1-2): 143-5.
130. Croonenberghs J, Bosmans E, Deboutte D, Kenis G, Maes M. Activation of the inflammatory response system in autism. Neuropsychobiology 2002; 45(1): 1-6.
131. Li X, Chauhan A, Sheikh AM, et al. Elevated immune response in the brain of autistic patients. J Neuroimmunol 2009; 207(1-2): 111-6.
132. Ashwood P, Nguyen DV, Hessl D, Hagerman RJ, Tassone F. Plasma cytokine profiles in Fragile X subjects: is there a role for cytokines in the pathogenesis? Brain Behav Immun 2010; 24(6): 898-902.
133. Suzuki K, Sugihara G, Ouchi Y, et al. Microglial activation in young adults with autism spectrum disorder. JAMA Psychiatry 2013; 70(1): 49-58.
134. Ricci S, Businaro R, Ippoliti F, et al. Altered cytokine and BDNF levels in autism spectrum disorder. Neurotox Res 2013; 24(4): 491-501.
135. Mead J, Ashwood P. Evidence supporting an altered immune response in ASD. Immunol Lett 2015; 163(1): 49-55.
136. Okada K, Hashimoto K, Iwata Y, et al. Decreased serum levels of transforming growth factor-beta1 in patients with autism. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31(1): 187-90.
137. Ashwood P, Enstrom A, Krakowiak P, et al. Decreased transforming growth factor beta1 in autism: a potential link between immune dysregulation and impairment in clinical behavioral outcomes. J Neuroimmunol 2008; 204(1-2): 149-53.
138. Masi A, Quintana DS, Glozier N, Lloyd AR, Hickie IB, Guastella AJ. Cytokine aberrations in autism spectrum disorder: a systematic review and meta-analysis. Mol Psychiatry 2015; 20(4): 440-6.
139. Zerbo O, Yoshida C, Grether JK, et al. Neonatal cytokines and chemokines and risk of Autism Spectrum Disorder: the Early Markers for Autism (EMA) study: a case-control study. J Neuroinflammation 2014; 11: 113.
140. Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo CA. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol 2005; 57(1): 67-81.
141. Chez MG, Dowling T, Patel PB, Khanna P, Kominsky M. Elevation of tumor necrosis factor-alpha in cerebrospinal fluid of autistic children. Pediatr Neurol 2007; 36(6): 361-5.
142. Caraci F, Gulisano W, Guida CA, et al. A key role for TGF-β1 in hippocampal synaptic plasticity and memory. Sci Rep 2015; 5: 11252.
143. Butovsky O, Jedrychowski MP, Moore CS, et al. Identification of a unique TGF-β-dependent molecular and functional signature in microglia. Nat Neurosci 2014; 17(1): 131-43.
144. Depino AM, Lucchina L, Pitossi F. Early and adult hippocampal TGF-β1 overexpression have opposite effects on behavior. Brain Behav Immun 2011; 25(8): 1582-91.
145. Morgan JT, Chana G, Pardo CA, et al. Microglial activation and increased microglial density observed in the dorsolateral prefrontal cortex in autism. Biol Psychiatry 2010; 68: 368-76.
146. Morgan JT, Chana G, Abramson I, Semendeferi K, Courchesne E, Everall IP. Abnormal microglial-neuronal spatial organization in the dorsolateral prefrontal cortex in autism. Brain Res 2012; 1456: 72-81.
147. Tetreault NA, Hakeem AY, Jiang S, et al. Microglia in the cerebral cortex in autism. J Autism Dev Disord 2012; 42(12): 2569-84.
148. Morgan JT, Barger N, Amaral DG, Schumann CM. Stereological study of amygdale glial populations in adolescents and adults with autism spectrum disorder. PLoS One 2014; 9(10): e110356.
149. Edmonson C, Ziats MN, Rennert OM. Altered glial marker expression in autistic post-mortem prefrontal cortex and cerebellum. Mol Autism 2014; 5(1): 3.
150. Voineagu I, Wang X, Johnston P, et al. Transcriptomic analysis of autistic brain reveals convergent molecular pathology. Nature 2011; 474(7351): 380-4.
151. Garbett K, Ebert PJ, Mitchell A, et al. Immune transcriptome alterations in the temporal cortex of subjects with autism. Neurobiol Dis 2008; 30(3): 303-11.
152. Ziats MN, Rennert OM. Expression profiling of autism candidate genes during human brain development implicates central immune signaling pathways. PLoS One 2011; 6(9): e24691.
153. Gupta S, Ellis SE, Ashar FN, et al. Transcriptome analysis reveals dysregulation of innate immune response genes and neuronal activity-dependent genes in autism. Nat Commun 2014; 5: 5748.
154. Crawford DC, Acuna JM, Sherman SL. FMR1 and the fragile X syndrome: human genome epidemiology review. Genet Med 2001; 3(5): 359-71.
155. Hagerman PJ. The fragile X prevalence paradox. J Med Genet 2008; 45(8): 498-9.
156. Verkerk AJ, Pieretti M, Sutcliffe JS, et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 1991; 65(5): 905-14.
157. Santoro MR, Bray SM, Warren ST. Molecular mechanisms of fragile X syndrome: a twenty-year perspective. Annu Rev Pathol 2012; 7: 219-45.
158. Alpatov R, Lesch BJ, Nakamoto-Kinoshita M, et al. A chromatindependent role of the fragile X mental retardation protein FMRP in the DNA damage response. Cell 2014; 157(4): 869-81.
159. Hagerman JR. Fragile X syndrome in Neurodevelopment Disorder. Diagnosis and treatment Oxford University Press, 1999.
160. Harris SW, Hessl D, Goodlin-Jones B, et al. Autism profiles of males with fragile X syndrome. Am J Ment Retard 2008; 113(6): 427-38.
161. Hagerman R, Hoem G, Hagerman P. Fragile X and autism: Intertwined at the molecular level leading to targeted treatments. Mol Autism 2010; 1: 12.
162. Musumeci SA, Hagerman RJ, Ferri R, et al. Epilepsy and EEG findings in males with fragile X syndrome. Epilepsia 1999; 40(8): 1092-9.
163. Berry-Kravis E. Epilepsy in fragile X syndrome. Dev Med Child Neurol 2002; 44(11): 724-8.
164. Careaga M, Noyon T, Basuta K, et al. Group I metabotropic glutamate receptor mediated dynamic immune dysfunction in children with fragile X syndrome. J Neuroinflammation 2014; 11: 110.
165. D’Antoni S, Spatuzza M, Bonaccorso CM, et al. Dysregulation of group-I metabotropic glutamate (mGlu) receptor mediated signalling in disorders associated with Intellectual Disability and Autism. Neurosci Biobehav Rev 2014; 46(2): 228-41.
166. Zantomio D, Chana G, Laskaris L, et al. Convergent evidence for mGluR5 in synaptic and neuroinflammatory pathways implicated in ASD. Neurosci Biobehav Rev 2015; 52: 172-7.
167. D’Antoni S, Berretta A, Bonaccorso CM, et al. Metabotropic glutamate receptors in glial cells. Neurochem Res 2008; 33(12): 2436-43.
168. Byrnes KR, Stoica B, Loane DJ, Riccio A, Davis MI, Faden AI. Metabotropic glutamate receptor 5 activation inhibits microglial associated inflammation and neurotoxicity. Glia 2009; 57(5): 550-60.
169. Byrnes KR, Loane DJ, Stoica BA, Zhang J, Faden AI. Delayed mGluR5 activation limits neuroinflammation and neurodegeneration after traumatic brain injury. J Neuroinflammation 2012; 9: 43.
170. Pacey LK, Doering LC. Developmental expression of FMRP in the astrocyte lineage: implications for fragile X syndrome. Glia 2007; 55(15): 1601-9.
171. Bonaccorso CM, Spatuzza M, Di Marco B, et al. Fragile X mental retardation protein (FMRP) interacting proteins exhibit different expression patterns during development. Int J Dev Neurosci 2015; 42: 15-23.
172. Gholizadeh S, Halder SK, Hampson DR. Expression of fragile X mental retardation protein in neurons and glia of the developing and adult mouse brain. Brain Res 2015; 1596: 22-30.
173. Winarni TI, Chonchaiya W, Sumekar TA, et al. Immune-mediated disorders among women carriers of fragile X premutation alleles. Am J Med Genet A 2012; 158A(10): 2473-81.
174. Chonchaiya W, Tassone F, Ashwood P, et al. Autoimmune disease in mothers with the FMR1 premutation is associated with seizures in their children with fragile X syndrome. Hum Genet 2010; 128(5): 539-48.
175. Yuskaitis CJ, Beurel E, Jope RS. Evidence of reactive astrocytes but not peripheral immune system activation in a mouse model of Fragile X syndrome. Biochim Biophys Acta 2010; 1802(11): 1006-12.
176. Pacey LK, Doering LC. Developmental expression of FMRP in the astrocyte lineage: implications for fragile X syndrome. Glia 2007; 55(15): 1601-9.
177. Bilousova TV, Dansie L, Ngo M, et al. Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J Med Genet 2009; 46: 94-102.
178. Sidhu H, Dansie LE, Hickmott PW, Ethell DW, Ethell IM. Genetic removal of matrix metalloproteinase 9 rescues the symptoms of fragile X syndrome in a mouse model. J Neurosci 2014; 34(30): 9867-79.
179. Leigh MJ, Nguyen DV, Mu Y, et al. A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile x syndrome. J Dev Behav Pediatr 2013; 34(3): 147-55.
180. Dansie LE, Phommahaxay K, Okusanya AG, et al. Long-lasting effects of minocycline on behavior in young but not adult Fragile X mice. Neuroscience 2013; 246: 186-98.
181. Mhatre M, Floyd RA, Hensley K. Oxidative stress and neuroinflammation in Alzheimer’s disease and amyotrophic lateral sclerosis: common links and potential therapeutic targets. J Alzheimers Dis 2004; 6(2): 147-57.
182. Niranjan R. The role of inflammatory and oxidative stress mechanisms in the pathogenesis of Parkinson’s disease: focus on astrocytes. Mol Neurobiol 2014; 49(1): 28-38.
183. Fischer R, Maier O. Interrelation of oxidative stress and inflammation in neurodegenerative disease: role of TNF. Oxid Med Cell Longev 2015; 2015: 610813.
184. el Bekay R, Romero-Zerbo Y, Decara J, et al. Enhanced markers of oxidative stress, altered antioxidants and NADPH-oxidase activation in brains from Fragile X mental retardation 1-deficient mice, a pathological model for Fragile X syndrome. Eur J Neurosci 2007; 26(11): 3169-80.
185. Davidovic L, Navratil V, Bonaccorso CM, Catania MV, Bardoni B, Dumas ME. A metabolomic and systems biology perspective on the brain of the fragile X syndrome mouse model. Genome Res 2011; 21(12): 2190-202.
186. Bechara EG, Didiot MC, Melko M, et al. A novel function for fragile X mental retardation protein in translational activation. PLoS Biol 2009; 7(1): e16.
187. de Diego-Otero Y, Romero-Zerbo Y, el Bekay R, et al. Alphatocopherol protects against oxidative stress in the fragile X knockout mouse: an experimental therapeutic approach for the Fmr1 deficiency. Neuropsychopharmacology 2009; 34(4): 1011-26.
188. Qin M, Kang J, Smith CB. Increased rates of cerebral glucose metabolism in a mouse model of fragile X mental retardation. Proc Natl Acad Sci USA 2002; 99(24): 15758-63.
189. Rett A. On a unusual brain atrophy syndrome in hyperammonemia in childhood. Wien Med Wochenschr 1966; 116(37): 723-6.
190. Hagberg B, Aicardi J, Dias K, Ramos O. A progressive syndrome of autism, dementia, ataxia, and loss of purposeful hand use in girls: Rett’s syndrome: report of 35 cases. Ann Neurol 1983; 14(4): 471-9.
191. Chahrour M, Zoghbi HY. The story of Rett syndrome: from clinic to neurobiology. Neuron 2007; 56(3): 422-37.
192. Liyanage VR, Rastegar M. Rett syndrome and MeCP2. Neuromolecular Med 2014; 16(2): 231-64.
193. Percy AK. Rett syndrome: exploring the autism link. Arch Neurol 2011; 68(8): 985-9.
194. Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet 1999; 23(2): 185-8.
195. Bedogni F, Rossi RL, Galli F, et al. Rett syndrome and the urge of novel approaches to study MeCP2 functions and mechanisms of action. Neurosci Biobehav Rev 2014; 46(2): 187-201.
196. Nan X, Campoy FJ, Bird A. MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 1997; 88(4): 471-81.
197. Jones PL, Veenstra GJ, Wade PA, et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 1998; 19(2): 187-91.
198. Nan X, Bird A. The biological functions of the methyl-CpGbinding protein MeCP2 and its implication in Rett syndrome. Brain Dev 2001; 23(1): S32-7.
199. Chahrour M, Jung SY, Shaw C, et al. MeCP2, a key contributor to neurological disease, activates and represses transcription. Science 2008; 320(5880): 1224-9.
200. Hansen JC, Ghosh RP, Woodcock CL. Binding of the Rett syndrome protein, MeCP2, to methylated and unmethylated DNA and chromatin. IUBMB Life 2010; 62(10): 732-8.
201. Shahbazian MD, Antalffy B, Armstrong DL, Zoghbi HY. Insight into Rett syndrome: MeCP2 levels display tissue- and cell-specific differences and correlate with neuronal maturation. Hum Mol Genet 2002; 11(2): 115-24.
202. Chen RZ, Akbarian S, Tudor M, Jaenisch R. Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat Genet 2001; 27(3): 327-31.
203. Kishi N, Macklis JD. MECP2 is progressively expressed in postmigratory neurons and is involved in neuronal maturation rather than cell fate decisions. Mol Cell Neurosci 2004; 27(3): 306-21.
204. Singleton MK, Gonzales ML, Leung KN, et al. MeCP2 is required for global heterochromatic and nucleolar changes during activitydependent neuronal maturation. Neurobiol Dis 2011; 43(1): 190-200.
205. Noutel J, Hong YK, Leu B, Kang E, Chen C. Experiencedependent retinogeniculate synapse remodeling is abnormal in MeCP2-deficient mice. Neuron 2011; 70(1): 35-42.
206. Armstrong DD. Neuropathology of Rett syndrome. J Child Neurol 2005; 20(9): 747-53.
207. Alvarez-Saavedra M, Sáez MA, Kang D, Zoghbi HY, Young JI. Cell-specific expression of wild-type MeCP2 in mouse models of Rett syndrome yields insight about pathogenesis. Hum Mol Genet 2007; 16(19): 2315-25.
208. Maezawa I, Swanberg S, Harvey D, LaSalle JM, Jin LW. Rett syndrome astrocytes are abnormal and spread MeCP2 deficiency through gap junctions. J Neurosci 2009; 29(16): 5051-61.
209. Ballas N, Lioy DT, Grunseich C, Mandel G. Non-cell autonomous influence of MeCP2-deficient glia on neuronal dendritic morphology. Nat Neurosci 2009; 12(3): 311-7.
210. Maezawa I, Jin LW. Rett syndrome microglia damage dendrites and synapses by the elevated release of glutamate. J Neurosci 2010; 30(15): 5346-56.
211. Cronk JC, Derecki NC, Ji E, et al. Methyl-CpG Binding Protein 2 Regulates Microglia and Macrophage Gene Expression in Response to Inflammatory Stimuli. Immunity 2015; 42(4): 679-91.
212. Lioy DT, Garg SK, Monaghan CE, et al. A role for glia in the progression of Rett’s syndrome. Nature 2011; 475(7357): 497-500.
213. Yasui DH, Xu H, Dunaway KW, Lasalle JM, Jin LW, Maezawa I. MeCP2 modulates gene expression pathways in astrocytes. Mol Autism 2013; 4(1): 3.
214. Derecki NC, Cronk JC, Lu Z, et al. Wild-type microglia arrest pathology in a mouse model of Rett syndrome. Nature 2012; 484(7392): 105-9.
215. Sawalha AH, Webb R, Han S, et al. Common variants within MECP2 confer risk of systemic lupus erythematosus. PLoS One 2008; 3(3): e1727.
216. Webb R, Wren JD, Jeffries M, et al. Variants within MECP2, a key transcription regulator, are associated with increased susceptibility to lupus and differential gene expression in patients with systemic lupus erythematosus. Arthritis Rheum 2009; 60(4): 1076-84.
217. Cobb BL, Fei Y, Jonsson R, et al. Genetic association between methyl-CpG binding protein 2 (MECP2) and primary Sjogren’s syndrome. Ann Rheum Dis 2010; 69(9): 1731-2.
218. Reichelt KL, Skjeldal O. IgA antibodies in Rett syndrome. Autism 2006; 10(2): 189-97.
219. Cortelazzo A, De Felice C, Guerranti R, et al. Subclinical inflammatory status in Rett syndrome. Mediat Inflamm 2014; 2014: 480980.
220. De Felice C, Signorini C, Leoncini S, et al. The role of oxidative stress in Rett syndrome: an overview. Ann NY Acad Sci 2012; 1259: 121-35.
221. Griffin WS, Stanley LC, Ling C, et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci USA 1989; 86(19): 7611-5.
222. Cuadrado E, Barrena MJ. Immune dysfunction in Down’s syndrome: primary immune deficiency or early senescence of the immune system? Clin Immunol Immunopathol 1996; 78(3): 209-14.
223. Cetiner S, Demirhan O, Inal TC, Tastemir D, Sertdemir Y. Analysis of peripheral blood T-cell subsets, natural killer cells and serum levels of cytokines in children with Down syndrome. Int J Immunogenet 2010; 37(4): 233-7.
224. Xue QS, Streit WJ. Microglial pathology in Down syndrome. Acta Neuropathol 2011; 122(4): 455-66.
225. Wilcock DM, Griffin WS. Down’s syndrome, neuroinflammation, and Alzheimer neuropathogenesis. J Neuroinflammation 2013; 10: 84.
226. Ling KH, Hewitt CA, Tan KL, et al. Functional transcriptome analysis of the postnatal brain of the Ts1Cje mouse model for Down syndrome reveals global disruption of interferon-related molecular networks. BMC Genom 2014; 15: 624.
227. Iulita MF, Cuello AC. Nerve growth factor metabolic dysfunction in Alzheimer’s disease and Down syndrome. Trends Pharmacol Sci 2014; 35(7): 338-48.
228. Prabowo AS, Anink JJ, Lammens M, et al. Fetal brain lesions in tuberous sclerosis complex: TORC1 activation and inflammation. Brain Pathol 2013; 23(1): 45-59.